Wanbury Limited (BOM:524212)

Market Cap	8.60B -6.6%
Revenue (ttm)	6.53B +3.3%
Net Income	558.87M +30.0%
EPS	16.34 +29.9%
Shares Out	34.89M
PE Ratio	15.09
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,491
Open	246.85
Previous Close	244.00
Day's Range	242.95 - 248.05
52-Week Range	162.00 - 360.00
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Wanbury

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its n...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 1,382
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524212

Financial Performance

In fiscal year 2026, Wanbury's revenue was 6.50 billion, an increase of 8.35% compared to the previous year's 6.00 billion. Earnings were 661.35 million, an increase of 116.62%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 6, 2026

Data Sources Report a data error